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Abstract- Biomolecular behavior of tumor cells has become attractive to investigators. p53 as an 
oncosuppresor gene has been core of various studies and Ki67 is a nuclear protein involved in 
proliferation process. Stopping of onco-suppressor function theoretically allows proliferative system to 
get out of any control. In this case-control study we evaluated 50 patients with non small cell lung 
cancer, considering the association between P53 oncoprotein and Ki67 with rate of tumoral cells 
differentiation. We found the concurrent move of P53 and Ki67 according to the rate of differentiation 
and a significant risk (odds ratio) for being poorly differentiated in samples having higher rates of these 
two factors. We suppose that mutant P53 protein not only may be used as an objective finding for tumor 
grading, but probably as a practical point of approach for determining prognosis and planning therapy 
for this patients. 
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INTRODUCTION 
 
Non small cell lung carcinoma (NSCLC) has been 
studied epidemiologically and etiologically  and from 
many other aspects during the past decade. One of 
the most important influencing  factors for predicting 
the outcome of patient is biological behavior of 
neoplasm (1-6).  
 Apart from conventional stage and grading 
systems, the oncogenes and proliferation factors  at 
biomolecular levels have critical importance for 
management of the patient and  biological 
classification of tumors (3, 7-10). Mutation of p53 
gene is known as a proto- oncogenic state of most 
cancers as well as NSCLC (1, 7, 14). We know that 
as its  oncosuppresor  control  effect  is  removed,  the       
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cell will be allowed  to accept more and more 
 mutations, above DNA repair system capacity, and 
this gets rise to poor differentiation. On the  other 
hand, cell’s proliferation system will act 
autonomically out of control. So theoretically,  the 
poorer differentiation grade, the higher proliferation 
rate. Ki67 is a cell cycle  associated antigen of nuclear 
matrix which express in all cell growth phases except 
 resting phase (G0) (15). Number of cells stained 
positively by monoclonal Ki67 antibody  correlates 
with tissue proliferation rate and grade (15, 16). This 
study was designed to  check this concept and also the 
relation between the Ki67 and P53  expression. 
 
MATERIALS AND METHODS 
 
In this case-control study 50 patients from two 
medical center, Shariati and Rassoul Akram 
Hospitals, diagnosed as NSCLC from 1999 to 2003, 
seen by two separate pathologist were included  and 
divided into two group of high grade tumor (as cases) 
and low grade tumor (as controls).  
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 Case group included 19 patients with high grade 
NSCLC  and  control group included 31 patients with 
low grade NSCLC.  
 When the grade of tumors were proved by light 
microscope according to WHO format,  cases and 
controls were selected based on their tumoral cell 
differentiation grade and anaplastic  changes. 
Immuno-histochemistry studies for two markers, P53 
mutant oncoprotein and Ki67  protein, was performed 
on blocks by using ABC method as described below. 
For analyzing the  content of P53 oncoprotein and Ki-
67 at nuclear membrane level, image cytometric 
method  was used. This method is a dry computerized 
microspectrophotometric method using a CCD- 
 camera adapted to Leitz microscopy and PIII 
hardware. The 410 nm filter was used for  detecting 
the best light absorbance. The DAB deposition on 
nuclear membrane for P53 was  divided in two 
separate group; those having the OD less than 300 
pixels were graded as 1+  [group light (L)] and those 
having more than 300 pixels were graded as 2+ 
[group heavy (H)] (17).  The same tabulation was 
used for Ki67 at nuclear cytosol stained by DAB. P53 
mutant  oncoprotein was detected by DO7 
monoclonal antibody and kit PAb180l (DAKO) 
which  detects only the mutant P53 protein, and Ki67 
by DAKO. Avidin-Biotin  method and DAB as 
chromogen were used in both tests. Agreement of 
two markers P53 and Ki67 was tested by  Kappa. 
Odds ratio for each factor was calculated with its 
confidence interval at significance  level of 5%. 
 
 
RESULTS 
 
Case group included 19 patients, 17 of them 
(%89.5) had P53 level of 2+; remaining 2  (%10.5) 
had P53 level of 1+. Rates of Ki67 were 2+ in 9 
patients (%47.4) and 1+ in 7 patients  (%36.8). 
Findings of 3 other patients (%15.8) were nonspecific 
and non-diagnostic (Fig. 1).  
Control group  included 31 patients, 11 of which 
(%35.5) had P53 level of 2+, 18 patients (%58.1) had 
 P53 level of 1+; findings in 2 patients (%6.4) were 
nonspecific. Rates of Ki67 were 2+ in 3 patients 
 (%9.7) and 1+ in 23 patients (%74.2); findings were 
nonspecific in 5 others (%16.1).  
P53 and Ki67  markers had well concordance in 
all patients; %40.5 had level of 1+,  and %25 had 
level of 2+ (Kappa = 0.257, P < 0.007), (Table 1). 
Results showed that low  expression of mutant P53 in 
controls is accompanied by low proliferation index 
(low Ki67) and increased intensity of  mutant P53 on 
nuclear membrane is accompanied by increased 
proliferating index (odds ratio = 13.9  , CI [%95]= 
2.7-72.1) and Ki67 (odds ratio= 9.9, CI [%95]= 2.1- 
46.7) (Table 2).  Lower expression of P53 and Ki67 
had the same concordance. 
 
 
 
 
 
 
 
 
 
                                         A                                                                                                    B 
 
 
 
 
 
 
 
 
 
 
                                         C                                                                                                    D 
Fig.1. Samples of positive and negative staining. A and B, 2+ P53; C, 2+ Ki67; D, negative P53. 
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Table 1. Agreement of P53 and Ki67 
 P53 1+ P53 2+ Total 
Ki67 1+ 17 11 28 
Ki67 2+ 2 10 12 
Total  19 21 40 
 
 
DISCUSSION 
 
Various studies have shown the role of genetic 
alterations in neoplastic cells (1, 7).  Among them, 
p53 as a suppressor gene is well studied in the last 
decade (14, 8). It can induce  many form of human 
cancers through three processes (1, 2); homozygous 
loss, inactivation of  both p53 alleles and inheritance 
of one mutant allele predisposing to inactivation of 
the second  one. Furthermore, some investigators have 
found positive correlation between these genetic 
 disorders predisposing to cancer and some 
environmental agents like tobacco, alcohol  and coal 
(18-20). Concurrent appearance of Ki67 and P53 
shows that by omission of suppressor effect of p53, 
 the proliferation rate rises autonomically and that’s 
just when we find the cell full of mutant  P53 protein 
accompanied by Ki67 nuclear antigen detecting by 
their monoclonal antibodies  (21). Only exceptions are 
complete omission of two p53 alleles and conditions 
with a high  proliferation rate out of the p53 control, 
which are not concern of this study.  
Hollstein et al. (1), Esposito et al.  (7) and 
Kleihues et al. (14) have shown that p53 mutation is 
inherited  in some families and carriers are at risk of 
malignant process, mean age of which differs  from 
16 years for sarcoma to 50 years for lung cancer. 
They believe  this  process  to be  entirly endogenous  
 
Table 2. Risk of tumor cell differentiation for level of P53 
and Ki67  
Tumor cell 
differentiation 
 
Low 
grade 
High 
grade 
Odds 
ratio 
CI (95%) 
P53 1+ 18 2 
P53 2+ 11 17 
13.9 (2.7-72.1) 
Ki67 1+ 23 7 
Ki67 2+ 3 9 
9.9 (2.1-46.7) 
but many others including Rom et al. (3), Leopardi et 
al. (21), Shibe et al.   (18) and Ahrendet et al. (20) 
suggest the role of environmental mutagenic factors 
such as  DNA viruses. Boggs et al. (19) reported over-
expression of P53 protein in sputum  of lung cancer 
patients who had been exposed to coal smoke. 
Ahrendet et al.  have shown that  alcohol impairs the 
action of tumor suppressing gene of p53 in smokers 
with lung cancer (20) and  researchers believe that 
there are a number of possible mechanisms 
responsible for alcohol’s  ability to increase the risk of 
p53 mutations in smokers developing lung cancer. 
Nichols et al. (4) and Birch et al. (22) believe that a 
dominantly inherited syndrome  of p53 mutation 
promotes a wide spectrum of early onset cancers. 
Giatromanolaki et al. showed  that angiogenesis is 
under control of p53 but there was no correlation 
between histology, grade,  proliferation index ( Ki67) 
and P53 expression in 107 operable NSCL cancers 
and  vascular proliferation was independent to P53 
expression (2).  
Considering proliferation marker (Ki67), Soomro 
et al. have shown that among 105 surgical cases of 
NSCLC, only  patients with Ki67 scores of less than 
5% did survive significantly longer than the rest (15). 
 Histology had no predictive value in determining 
prognosis in both operable  and inoperable groups; in 
a follow-up with mean duration of 20 months, Ki67 
antibody was promising in  identifying low and high 
grade disease in the initial stages of lung cancer. 
Nguyen et al.  found that p53, bcl-2 and Ki67 
expression is seen in 30%, 69% and 39% of NSCLC 
cases,  respectively (23). They concluded that none of 
the markers can be used as an independent prognostic 
 factor, whereas combination of them such as P53 
positivity +  low Ki-67 expression, P53 positivity + 
lack of cyclin-Dl expression and bcl-2 positivity + 
low Ki67 have a favorable prognostic value. 
Franciosi et al. showed that P53 and Ki67 were 
positive in 53% and 50% of FNA samples  of lung 
tumors, respectively and this measurement can be 
used as a low invasive procedure before treatment 
planning  of NSCLC (24).  
In conclusion, our findings suggest that 
prevalence of P53 in NSCLC grows quantitively 
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 according to the tumor grade, and just concurrent to 
the Ki67 marker. So detecting the  mutant P53 protein 
in NSCLC not only can play an important role as a 
morpho-  pathologic determinant of its grade (11), but 
also as a criterion of its proliferating manner. It can also 
be probably used for monitoring and predicting the 
stage of disease and at least helps planning therapy. 
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